Table 1.
Patient characteristics and total number of bone metastases with 18F-fluoride PET/CT uptake
| Patients’ ID | Age at diagnosis | Gleason at diagnosis | PSA at baseline | Ongoing treatment | Total number of bone metastases |
|---|---|---|---|---|---|
| 1 | 82 | 3 + 4 | 50 | Denosumab, GnRH analogue (goserelin), calcium tablets | 27 |
| 2 | 80 | 4 + 3 | 0.4 | GnRH analogue (goserelin), calcium tablets | 15 |
| 3 | 79 | 4 + 5 | 14 | Anti-androgen (bicalutamid), GnRH analogue (goserelin) | 22 |
| 4 | 79 | 5 + 4 | 0.5 | Denosumab, GnRH analogue (goserelin), dexamethasone, calcium tablets | 10 |
| 5 | 77 | 4 + 5 | 33 | Abiraterone, denosumab, GnRH analogue (goserelin), dexamethasone, calcium tablets | 29 |
| 6 | 77 | 3 + 4 | 96 | Denosumab, GnRH analogue (goserelin), | 122 |
| 7 | 71 | 3 + 4 | 1000 | Denosumab, GnRH analogue (goserelin), prednisolone, calcium tablets | 2 |
| 8 | 69 | 3 + 4 | 341 | Abiraterone, denosumab, GnRH analogue (goserelin), dexamethasone, calcium tablets | 17 |
| 9 | 62 | 5 + 4 | 43 | Denosumab, GnRH analogue (goserelin), calcium tablets | 7 |
| 10 | 70 | 5 + 5 | 91 | Abiraterone, denosumab, prednisolone, calcium tablets | 40 |